Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334512 · ClinicalTrials.gov registry record · Phase 2
A Study of Quintuple Therapy to Treat COVID-19 Infection
A Phase 2 study, sponsored by ProgenaBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT04334512: Completed Phase 2 study, sponsored by ProgenaBiome.
NCT04334512 is a Phase 2 study that has completed, run by ProgenaBiome. The registered enrollment target is 118 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04334512, a Phase 2 study, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).
Primary Outcome
Number of days from COVID-19 diagnosis to recovery via RT-PCR
Interventions
- DRUG Azithromycin
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Hydroxychloroquine
- DIETARY_SUPPLEMENT Vitamin C
- DIETARY_SUPPLEMENT Zinc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 2 |
What the finished NCT04334512 record still lists
NCT04334512 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 5 interventions - of which Azithromycin is the first listed.
NCT04334512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04334512 about?
NCT04334512 is a clinical study titled "A Study of Quintuple Therapy to Treat COVID-19 Infection". This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).
What is the current status of trial NCT04334512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2020-06-22. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT04334512?
The interventions under investigation include: Azithromycin (DRUG), Vitamin D (DIETARY_SUPPLEMENT), Hydroxychloroquine (DRUG), Vitamin C (DIETARY_SUPPLEMENT), Zinc (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04334512?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04334512's enrollment target sits among peer trials
118 618th of 2000 higher than 1,378 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI